How do you decide on 2nd line therapy in a patient with HER2+ metastatic esophageal/gastric cancer who progresses after initial response to trastuzumab-based chemotherapy?  

Are there factors that would lead you to select either ramucirumab +/- paclitaxel vs T-Dxd vs chemo?



Answer from: Medical Oncologist at Academic Institution
Comments
Medical Oncologist at UH Samaritan Medical Center
@Afsaneh Barzi, would you consider immunotherapy f...
Sign in or Register to read more

Answer from: Medical Oncologist at Community Practice

Answer from: Medical Oncologist at Academic Institution

Answer from: Medical Oncologist at Academic Institution

Answer from: Medical Oncologist at Academic Institution

Answer from: Medical Oncologist at Academic Institution